University of Cambridge — Biomedical Watch V2

Traitements16programmes

Essais14liés

Publications3liées

SourceDBlocale

Traitements

16

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
AnifrolumabThis is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive anifrolumab compared with a comparable population of moderate/severe SLE patients on standard of care who do not initiate anifrolumab.	Lupus, Myopathies	Non applicable	À vérifier	United Kingdom	À vérifier
Met-Pro — The Role of METhanogens in the PROgression Of Parkinson's Disease and Related Neurological ConditionsGut problems, such as constipation, can have an important impact on quality of life of people who have them, and have been associated with higher risk of developing neurological diseases such as Parkinson's or Alzheimer's disease. Recent studies suggest that gut problems may also have implications for the progression of these diseases, as constipation is a risk factor for faster Parkinson's and Alzheimer's progression. However, how constipation and brain diseases are linked is unknown. Previous research has suggested that gut changes may lead to inflammation, which could play a role in accelerating the progression of both movement and memory problems in Parkinson's and memory and thinking problems in people with cognitive impairment. Methane is a gas that is naturally produced by microorganisms in the gut. Levels of methane can be measured using a simple breath test. Higher methane levels in the breath are thought to be more common in people with Parkinson's disease (PwP) when compared to people without Parkinson's (healthy controls) and have been associated with gut symptoms, particularly constipation, as well as worse movement problems in PwP, although they are less understood in conditions that affect memory and thinking (like dementia or mild cognitive impairment). The investigators want to better understand the changes in the gut of PwP and people with cognitive impairment (e.g. mild cognitive impairment or dementia). They will compare breath methane levels in PwP, people with cognitive impairment, people with REM Sleep Behaviour Disorder (a sleep condition linked to a higher risk of developing Parkinson's) and healthy participants. Participants will be followed-up over time to assess how methane levels are linked to changes in the blood and the stools, gut function, and clinical symptoms. This study has 2 components: Component 1: observational study, where the study investigators will follow 200 participants over 2 visits, 18 months apart. The study will recruit 4 groups of people: 50 people with Parkinson's disease, 50 people at high risk of developing Parkinson's disease (people with REM Sleep behaviour disorder), 50 people with other conditions affecting cognition (e.g. dementia, mild cognitive impairment), and 50 healthy controls. Component 2: study with 15 people with Parkinson's, who produce high methane levels, to test whether a probiotic (Lactobacillus reuteri) affects how much methane is produced.	Alzheimer, Parkinson	Non applicable	Ralentissement de la progression + Immunomodulation + Traitement symptomatique	United Kingdom	À vérifier
AnifrolumabThis is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive anifrolumab compared with a comparable population of moderate/severe SLE patients on standard of care who do not initiate anifrolumab.	Lupus	À vérifier	À vérifier	Denmark, France, Germany, Spain	À vérifier
AnifrolumabThis is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive anifrolumab compared with a comparable population of moderate/severe SLE patients on standard of care who do not initiate anifrolumab.	Lupus	À vérifier	À vérifier	Sweden	À vérifier
AnifrolumabThis is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive anifrolumab compared with a comparable population of moderate/severe SLE patients on standard of care who do not initiate anifrolumab.	Lupus	Phase 3	À vérifier	China	À vérifier
AnifrolumabThis is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive anifrolumab compared with a comparable population of moderate/severe SLE patients on standard of care who do not initiate anifrolumab.	Lupus	Phase 3	À vérifier	United States, Argentina, Belgium, Brazil, Bulgaria, China, Colombia, France, Germany, Hungary, India, Italy, Japan, Malaysia, Mexico, Netherlands, Peru, Poland, Puerto Rico, Russia, …	À vérifier
AnifrolumabThis is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive anifrolumab compared with a comparable population of moderate/severe SLE patients on standard of care who do not initiate anifrolumab.	Lupus	Phase 3	À vérifier	United States, Argentina, Brazil, Canada, China, Colombia, France, Germany, Italy, Japan, Mexico, Poland, Portugal, South Africa, Spain, Turkey (Türkiye), United Kingdom	À vérifier
AnifrolumabThis is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive anifrolumab compared with a comparable population of moderate/severe SLE patients on standard of care who do not initiate anifrolumab.	Lupus	Phase 3	À vérifier	United States, Canada, France, Germany, Italy, Mexico, Poland, Spain, Taiwan	À vérifier
AnifrolumabThis is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive anifrolumab compared with a comparable population of moderate/severe SLE patients on standard of care who do not initiate anifrolumab.	Lupus	À vérifier	À vérifier	Italy	À vérifier
AnifrolumabThis is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive anifrolumab compared with a comparable population of moderate/severe SLE patients on standard of care who do not initiate anifrolumab.	Lupus	Phase 4	À vérifier	United States	À vérifier
Met-Pro — The Role of METhanogens in the PROgression Of Parkinson's Disease and Related Neurological ConditionsGut problems, such as constipation, can have an important impact on quality of life of people who have them, and have been associated with higher risk of developing neurological diseases such as Parkinson's or Alzheimer's disease. Recent studies suggest that gut problems may also have implications for the progression of these diseases, as constipation is a risk factor for faster Parkinson's and Alzheimer's progression. However, how constipation and brain diseases are linked is unknown. Previous research has suggested that gut changes may lead to inflammation, which could play a role in accelerating the progression of both movement and memory problems in Parkinson's and memory and thinking problems in people with cognitive impairment. Methane is a gas that is naturally produced by microorganisms in the gut. Levels of methane can be measured using a simple breath test. Higher methane levels in the breath are thought to be more common in people with Parkinson's disease (PwP) when compared to people without Parkinson's (healthy controls) and have been associated with gut symptoms, particularly constipation, as well as worse movement problems in PwP, although they are less understood in conditions that affect memory and thinking (like dementia or mild cognitive impairment). The investigators want to better understand the changes in the gut of PwP and people with cognitive impairment (e.g. mild cognitive impairment or dementia). They will compare breath methane levels in PwP, people with cognitive impairment, people with REM Sleep Behaviour Disorder (a sleep condition linked to a higher risk of developing Parkinson's) and healthy participants. Participants will be followed-up over time to assess how methane levels are linked to changes in the blood and the stools, gut function, and clinical symptoms. This study has 2 components: Component 1: observational study, where the study investigators will follow 200 participants over 2 visits, 18 months apart. The study will recruit 4 groups of people: 50 people with Parkinson's disease, 50 people at high risk of developing Parkinson's disease (people with REM Sleep behaviour disorder), 50 people with other conditions affecting cognition (e.g. dementia, mild cognitive impairment), and 50 healthy controls. Component 2: study with 15 people with Parkinson's, who produce high methane levels, to test whether a probiotic (Lactobacillus reuteri) affects how much methane is produced.	Alzheimer	Non applicable	Ralentissement de la progression + Immunomodulation + Traitement symptomatique	United Kingdom	À vérifier
AnifrolumabThis is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive anifrolumab compared with a comparable population of moderate/severe SLE patients on standard of care who do not initiate anifrolumab.	Lupus	À vérifier	À vérifier	United States	À vérifier
AnifrolumabThis is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive anifrolumab compared with a comparable population of moderate/severe SLE patients on standard of care who do not initiate anifrolumab.	Lupus	Phase 2	À vérifier	United States	À vérifier
AnifrolumabThis is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive anifrolumab compared with a comparable population of moderate/severe SLE patients on standard of care who do not initiate anifrolumab.	Lupus	À vérifier	À vérifier	Poland	À vérifier
AnifrolumabThis is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive anifrolumab compared with a comparable population of moderate/severe SLE patients on standard of care who do not initiate anifrolumab.	Myopathies	Phase 3	À vérifier	United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, France, Germany, Greece, India, Israel, Italy, Japan, Mexico, …	À vérifier
AnifrolumabThis is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive anifrolumab compared with a comparable population of moderate/severe SLE patients on standard of care who do not initiate anifrolumab.	Lupus	Non applicable	Immunomodulation	United Kingdom	À vérifier

Essais cliniques

14

Molécule	Indication / population	Phase	NCT	Titre	Statut
Anifrolumab	Lupus	Non applicable	NCT07913919	AISLE — Effect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus Study	RECRUITING
Anifrolumab	Myopathies	Phase 3	NCT07691970	ROSY-S — Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment	RECRUITING
Anifrolumab	Lupus	À vérifier	NCT06673043	SLE-ARTEMIS — Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus	ACTIVE_NOT_RECRUITING
Anifrolumab	Lupus	Phase 2	NCT05440422	The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD	RECRUITING
Anifrolumab	Lupus	À vérifier	NCT06659029	PRIMULA_Preg — Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users	RECRUITING
Met-Pro — The Role of METhanogens in the PROgression Of Parkinson's Disease and Related Neurological Conditions	Alzheimer	Non applicable	NCT07786116	Met-Pro — The Role of METhanogens in the PROgression Of Parkinson's Disease and Related Neurological Conditions	RECRUITING
Anifrolumab	Lupus	Phase 4	NCT06594068	PRIMULA Lac — Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users	RECRUITING
Anifrolumab	Lupus	À vérifier	NCT07330245	DAHLIA — Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.	RECRUITING
Anifrolumab	Lupus	Phase 3	NCT07430306	SUNFLOWER — A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus	RECRUITING
Anifrolumab	Lupus	Phase 3	NCT05835310	BLOSSOM — An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants	RECRUITING
Anifrolumab	Lupus	Phase 3	NCT05138133	IRIS — Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis	ACTIVE_NOT_RECRUITING
Anifrolumab	Lupus	Phase 3	NCT07751848	LOTUS — A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus	RECRUITING
Anifrolumab	Lupus	À vérifier	NCT06795893	The Anifrolumab PRIM Program	RECRUITING
Anifrolumab	Lupus	À vérifier	NCT07000110	SIMA — Anifrolumab Malignancy and Serious Infections Study	RECRUITING

Publications

3

Molécule	Indication / population	Titre	Journal	Date
Anifrolumab		Anifrolumab versus Belimumab for Cardiovascular Disease Risk in Systemic Lupus Erythematosus.	Arthritis & rheumatology (Hoboken, N.J.)
Anifrolumab		Update to the Sociedad Española de Reumatología Guidelines on the Use of Biological Therapy in Systemic Lupus Erythematosus.	Reumatologia clinica
Anifrolumab		Early haematologic response to anifrolumab in systemic lupus erythematosus: results from the european multicentre EFFORT-SLE study.	Rheumatology (Oxford, England)